Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM

Gregory M. Martin, Balamurugan Kandasamy, Frank Dimaio, Craig Yoshioka, Show-Ling Shyng

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear where the drug binding pocket resides. Here, we present a cryo-EM structure of a hamster SUR1/rat Kir6.2 channel bound to a high-affinity sulfonylurea drug glibenclamide and ATP at 3.63 Å resolution, which reveals unprecedented details of the ATP and glibenclamide binding sites. Importantly, the structure shows for the first time that glibenclamide is lodged in the transmembrane bundle of the SUR1-ABC core connected to the first nucleotide binding domain near the inner leaflet of the lipid bilayer. Mutation of residues predicted to interact with glibenclamide in our model led to reduced sensitivity to glibenclamide. Our structure provides novel mechanistic insights of how sulfonylureas and ATP interact with the KATP channel complex to inhibit channel activity.

Original languageEnglish (US)
Article numbere31054
JournaleLife
Volume6
DOIs
StatePublished - Oct 16 2017

Fingerprint

KATP Channels
Glyburide
Binding Sites
Pharmaceutical Preparations
Adenosine Triphosphate
Lipid bilayers
Lipid Bilayers
Cricetinae
Nucleotides
Mutation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM. / Martin, Gregory M.; Kandasamy, Balamurugan; Dimaio, Frank; Yoshioka, Craig; Shyng, Show-Ling.

In: eLife, Vol. 6, e31054, 16.10.2017.

Research output: Contribution to journalArticle

Martin, Gregory M. ; Kandasamy, Balamurugan ; Dimaio, Frank ; Yoshioka, Craig ; Shyng, Show-Ling. / Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM. In: eLife. 2017 ; Vol. 6.
@article{306bd7dfd5c041668fba795b7cff3d9d,
title = "Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM",
abstract = "Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear where the drug binding pocket resides. Here, we present a cryo-EM structure of a hamster SUR1/rat Kir6.2 channel bound to a high-affinity sulfonylurea drug glibenclamide and ATP at 3.63 {\AA} resolution, which reveals unprecedented details of the ATP and glibenclamide binding sites. Importantly, the structure shows for the first time that glibenclamide is lodged in the transmembrane bundle of the SUR1-ABC core connected to the first nucleotide binding domain near the inner leaflet of the lipid bilayer. Mutation of residues predicted to interact with glibenclamide in our model led to reduced sensitivity to glibenclamide. Our structure provides novel mechanistic insights of how sulfonylureas and ATP interact with the KATP channel complex to inhibit channel activity.",
author = "Martin, {Gregory M.} and Balamurugan Kandasamy and Frank Dimaio and Craig Yoshioka and Show-Ling Shyng",
year = "2017",
month = "10",
day = "16",
doi = "10.7554/eLife.31054.001",
language = "English (US)",
volume = "6",
journal = "eLife",
issn = "2050-084X",
publisher = "eLife Sciences Publications",

}

TY - JOUR

T1 - Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM

AU - Martin, Gregory M.

AU - Kandasamy, Balamurugan

AU - Dimaio, Frank

AU - Yoshioka, Craig

AU - Shyng, Show-Ling

PY - 2017/10/16

Y1 - 2017/10/16

N2 - Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear where the drug binding pocket resides. Here, we present a cryo-EM structure of a hamster SUR1/rat Kir6.2 channel bound to a high-affinity sulfonylurea drug glibenclamide and ATP at 3.63 Å resolution, which reveals unprecedented details of the ATP and glibenclamide binding sites. Importantly, the structure shows for the first time that glibenclamide is lodged in the transmembrane bundle of the SUR1-ABC core connected to the first nucleotide binding domain near the inner leaflet of the lipid bilayer. Mutation of residues predicted to interact with glibenclamide in our model led to reduced sensitivity to glibenclamide. Our structure provides novel mechanistic insights of how sulfonylureas and ATP interact with the KATP channel complex to inhibit channel activity.

AB - Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2. The mechanism by which these drugs interact with and inhibit the channel has been extensively investigated, yet it remains unclear where the drug binding pocket resides. Here, we present a cryo-EM structure of a hamster SUR1/rat Kir6.2 channel bound to a high-affinity sulfonylurea drug glibenclamide and ATP at 3.63 Å resolution, which reveals unprecedented details of the ATP and glibenclamide binding sites. Importantly, the structure shows for the first time that glibenclamide is lodged in the transmembrane bundle of the SUR1-ABC core connected to the first nucleotide binding domain near the inner leaflet of the lipid bilayer. Mutation of residues predicted to interact with glibenclamide in our model led to reduced sensitivity to glibenclamide. Our structure provides novel mechanistic insights of how sulfonylureas and ATP interact with the KATP channel complex to inhibit channel activity.

UR - http://www.scopus.com/inward/record.url?scp=85032942597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032942597&partnerID=8YFLogxK

U2 - 10.7554/eLife.31054.001

DO - 10.7554/eLife.31054.001

M3 - Article

C2 - 29035201

AN - SCOPUS:85032942597

VL - 6

JO - eLife

JF - eLife

SN - 2050-084X

M1 - e31054

ER -